Deisseroth, Hegemann, and Nagel win Nobel for optogenetics, Daily Maverick says

How did pond algae inspire a medical revolution?

The scientific journey began with Peter Hegemann at Humboldt University of Berlin and Georg Nagel at the University of Würzburg, who wanted to understand how a tiny, single-celled alga called Chlamydomonas senses light. Hegemann and Nagel discovered that the alga relies on a single protein called channelrhodopsin, embedded in its outer membrane. Stanford University bioengineer and psychiatrist Karl Deisseroth later realized this protein could be engineered into nerve cells, allowing scientists to switch them on and off with precise beams of light.

Why does optogenetics matter for neuroscience?

Nerve cells naturally use the movement of charged ions across their membranes to control activity. This method acts as a light-sensitive switch, letting researchers map which cells control specific functions. In animal studies, such as a 2012 experiment at the Massachusetts Institute of Technology co-authored by Deisseroth, scientists used optical fibers to reactivate specific memory cells in mice, causing the animals to freeze in fear as if remembering a past shock. The Nobel committee noted that researchers have since identified neural circuits governing pain, social behaviors, reward, and attention.

What are the clinical applications for patients today?

Optogenetics has moved beyond basic research into early-stage clinical trials. In trials for retinal degeneration, researchers introduce light-sensitive proteins into surviving nerve cells in the retina after light-detecting rods and cones are lost, helping patients regain some vision and discern objects using special light-emitting glasses. Scientists are also investigating whether the technique could improve cochlear implants for hearing loss or treat neurological disorders like Parkinson’s and epilepsy. When the prize was announced on October 5, 2026, Nagel learned the news while on a terrace in Italy, telling reporters he never expected the honor, while Deisseroth experienced a brief moment of speechlessness during a briefing with his children.

What remains unknown about the future of light-controlled treatments?

Despite the expansion of optogenetics in laboratories worldwide, widespread clinical therapies remain in their infancy. David Pendlebury, head of research analysis at Clarivate, pointed out that very few patients have actually profited from optogenetics in a medical setting so far, leading some observers to consider a Nobel prize premature.

More on this story: 2026 Nobel Prize in Medicine Awarded for Breakthroughs in Optogenetics